Cita APA

Salvador-Bofill, J., Moreno, F., Rodriguez Sanchez, C. A., Galve Calvo, E., HERNANDO MELIA, C., Ciruelos, E., & Bellet Ezquerra, M. (2022). Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial.

Citación estilo Chicago

Salvador-Bofill, Javier, Fernando Moreno, Cesar Augusto Rodriguez Sanchez, Elena Galve Calvo, CRISTINA HERNANDO MELIA, Eva Ciruelos, y Meritxell Bellet Ezquerra. Safety and Efficacy of Ribociclib Plus Letrozole in Patients With HR+, HER2– Advanced Breast Cancer: Results From the Spanish Sub-population of the Phase 3b CompLEEment-1 Trial. 2022.

Cita MLA

Salvador-Bofill, Javier, et al. Safety and Efficacy of Ribociclib Plus Letrozole in Patients With HR+, HER2– Advanced Breast Cancer: Results From the Spanish Sub-population of the Phase 3b CompLEEment-1 Trial. 2022.